Amdoxovir

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Amdoxovir
Amdoxovir.svg
Systematic (IUPAC) name
[(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol
Clinical data
Identifiers
145514-04-1 YesY
None
PubChem CID 124088
ChemSpider 110576 YesY
UNII 54I81H0M9C YesY
KEGG D02890 YesY
ChEMBL CHEMBL458876 YesY
NIAID ChemDB 005431
Chemical data
Formula C9H12N6O3
252.23 g/mol
 YesY (what is this?)  (verify)

Amdoxovir is a nucleoside reverse transcriptase inhibitor (NRTI) undergoing research for the treatment of HIV/AIDS. It was discovered by Raymond F. Schinazi (Emory University) and C.K. Chu (University of Georgia). It is being developed by RFS Pharma.[1] Currently, it is in Phase II clinical studies.

References[edit]

  1. ^ "Amdoxovir". AIDSmeds.com. January 13, 2009. Archived from the original on March 21, 2008. Retrieved March 21, 2008. 

External links[edit]

  • Murphy RL, Kivel NM, Zala C, Ochoa C, Tharnish P, Mathew J, Pascual ML, Schinazi RF (2010). "Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals". Antivir Ther 15 (2): 185–192. doi:10.3851/IMP1514. PMID 20386073.